Acoustic AI · Respiratory Screening · India

TB. COPD. Asthma.
Detected from a cough
on any smartphone.

No app download. No specialized hardware. Trained on real Indian OPD conditions - not a laboratory.

Become a Research Site Investor Enquiry
Acoustic spectrogram - what the model sees
Log-Mel features extracted · Risk score generating…
30K+
Target confirmed-diagnosis cohort across 6 zones
500M+
Reachable via universal voice messaging
Validated
End-to-end acoustic pipeline verified on retrospective data
6
Epidemiological zones in active site onboarding

The Problem

Respiratory disease in India
is caught too late.

Acoustic biomarkers in a cough carry clinically significant diagnostic signal. Yet no screening model has been built for the real conditions of clinical deployment.

25%

India carries a quarter of the global TB burden - yet patients delay presentation until symptoms become severe and irreversible.

55M+

Indians live with chronic obstructive airway disease - overwhelmingly undiagnosed until permanent lung damage has occurred.

Lab ≠ Field

Prior acoustic models trained in clean laboratory settings collapse when exposed to ambient OPD noise, consumer microphones, and network audio compression.

How It Works

One cough. An objective risk score.

Designed for point-of-first-contact triage through low-bandwidth voice messaging - zero app installation required.

01
Capture Cough Audio
A short voluntary recording sent via standard mobile voice messaging. No new software to install.
→
02
Acoustic Feature Extraction
Log-Mel spectrogram features are extracted and evaluated against models trained on molecularly and objectively confirmed clinical ground truth.
→
03
Physician Decision Support
Elevated-risk individuals are prioritised for confirmatory diagnostics (GeneXpert or spirometry) earlier in their disease trajectory. Pre-screening only; diagnosis remains strictly with clinicians.

Zero New Infrastructure

The deployment infrastructure
is already in every pocket.

Designed to deploy at national scale without creating a single procurement or operational barrier.

✕

No App Download

✕

No Dedicated Hardware

✕

No Upfront CapEx

✕

No High-Speed Data

Where We're Building

Multiple zones. One national dataset.

Multi-site data collection active or being activated across India - capturing the full acoustic and demographic diversity of Indian respiratory disease.

Map of India with states shaded by Respiro Health's site-development stage
Advanced (MoU stage)
In active discussion
Early outreach
  • Southern Zone — MoU in Final Stages
  • North-Central Zone — Institutional Discussions
  • Western Zone — Multiple Sites in Discussion
  • Eastern Zone — Proposal Submitted
  • Capital Zone — Proposal Submitted
  • Western Himalayan Zone — Outreach Active
  • Northeast Zone — Outreach Active

The Vision

Starting with TB. Scaling across all respiratory disease.

A single national acoustic dataset and multimodal AI architecture engineered to generalize across clinical phenotypes and geographies.

01

Starts with TB

India's highest-burden infectious respiratory disease. Our initial disease-specific model targets presumptive TB triage anchored to molecular ground truth.

02

Differential Airway Triage

Simultaneous risk stratification for COPD, asthma, and acute lower respiratory conditions from the same audio capture.

03

National Generalisability

Recruited across six distinct epidemiological zones to ensure models perform robustly across regional acoustic and demographic variance.

We are not building a screening tool for a single clinic. We are building the acoustic respiratory intelligence layer for India.

Illustrative preview - the future patient experience, once validated
RH
Respiro Clinical Pre-Screen
Hello! Please record a 15-second voluntary cough.
10:02
0:17
10:03
Acoustic Pre-Screen Complete Elevated risk indicators detected. Prioritised for physician evaluation and confirmatory testing.
10:03

Work With Us

We're looking for the right partners.

Hospitals & Clinics

Chest and pulmonary OPDs as research sites. We fund and staff everything - you get named co-authorship and priority model access.

Network & Introductions

Warm introductions to hospital CMOs, medical directors, or health department decision-makers move faster than cold outreach.

Academic & Research

Medical institutions interested in clinical validation partnerships, co-authorship, or joint grant applications in respiratory AI.

Strategic Investors

Investors who understand the Indian healthcare market and bring clinical relationships alongside capital. Pre-seed round open.

Get Involved

India's respiratory disease burden
demands earlier detection.

Whether you lead a chest OPD, oversee a hospital department, invest in clinical deep-tech, or want to explore research collaboration - connect with us.

Get In Touch Our Research